Display options
Cite
Calagua C, Ficial M, Jansen CS, et al. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021;27(17):4836-4847doi: 10.1158/1078-0432.CCR-21-0121.
Calagua, C., Ficial, M., Jansen, C. S., Hirz, T., Del Balzo, L., Wilkinson, S., Lake, R., Ku, A. T., Voznesensky, O., Sykes, D. B., Saylor, P. J., Ye, H., Signoretti, S., Kissick, H., Sowalsky, A. G., Balk, S. P., & Einstein, D. J. (2021). A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4836-4847. https://doi.org/10.1158/1078-0432.CCR-21-0121
Calagua, Carla, et al. "A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4836-4847. doi: https://doi.org/10.1158/1078-0432.CCR-21-0121
Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021 Sep 01;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24. PMID: 34168052; PMCID: PMC8416924.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Sep 01;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24.

A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.

Clinical cancer research : an official journal of the American Association for Cancer Research

Carla Calagua, Miriam Ficial, Caroline S Jansen, Taghreed Hirz, Luke Del Balzo, Scott Wilkinson, Ross Lake, Anson T Ku, Olga Voznesensky, David B Sykes, Philip J Saylor, Huihui Ye, Sabina Signoretti, Haydn Kissick, Adam G Sowalsky, Steven P Balk, David J Einstein

Affiliations

  1. Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  2. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  3. Harvard Medical School, Boston, Massachusetts.
  4. Department of Urology, Emory University, Atlanta, Georgia.
  5. Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  6. Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts.
  7. Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  8. National Cancer Institute, Bethesda, Maryland.
  9. Department of Pathology, University of California, Los Angeles, Los Angeles, California.
  10. Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  11. Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. [email protected] [email protected].

PMID: 34168052 PMCID: PMC8416924 DOI: 10.1158/1078-0432.CCR-21-0121

Abstract

PURPOSE: A subset of primary prostate cancer expresses programmed death-ligand 1 (PD-L1), but whether they have a unique tumor immune microenvironment or genomic features is unclear.

EXPERIMENTAL DESIGN: We selected PD-L1-positive high-grade and/or high-risk primary prostate cancer, characterized tumor-infiltrating lymphocytes with multiplex immunofluorescence, and identified genomic alterations in immunogenic and nonimmunogenic tumor foci.

RESULTS: One quarter of aggressive localized prostate cancer cases (29/115) had tumor PD-L1 expression more than 5%. This correlated with increased density of CD8

CONCLUSIONS: A subset of localized prostate cancer is immunogenic, manifested by PD-L1 expression and CD8

©2021 American Association for Cancer Research.

References

  1. Clin Cancer Res. 2021 Jan 1;27(1):320-329 - PubMed
  2. J Clin Invest. 2017 Aug 1;127(8):2930-2940 - PubMed
  3. Cell. 2018 Nov 1;175(4):998-1013.e20 - PubMed
  4. Annu Rev Immunol. 2019 Apr 26;37:457-495 - PubMed
  5. Cell. 2018 Jun 14;173(7):1770-1782.e14 - PubMed
  6. Nat Rev Urol. 2018 Jan;15(1):11-24 - PubMed
  7. Clin Cancer Res. 2017 Nov 15;23(22):6812-6822 - PubMed
  8. J Exp Med. 2010 Sep 27;207(10):2175-86 - PubMed
  9. Science. 2018 Oct 12;362(6411): - PubMed
  10. Nature. 2016 Sep 15;537(7620):417-421 - PubMed
  11. Nature. 2017 Jan 18;541(7637):321-330 - PubMed
  12. Target Oncol. 2016 Jun;11(3):345-51 - PubMed
  13. J Exp Med. 2010 Sep 27;207(10):2187-94 - PubMed
  14. JAMA Oncol. 2019 Aug 1;5(8):1195-1204 - PubMed
  15. Ann Oncol. 2017 Jul 1;28(7):1495-1507 - PubMed
  16. Nature. 2018 Jul;559(7714):363-369 - PubMed
  17. Immunity. 2018 May 15;48(5):1029-1045.e5 - PubMed
  18. J Clin Oncol. 2020 Feb 10;38(5):395-405 - PubMed
  19. Nat Immunol. 2019 Mar;20(3):326-336 - PubMed
  20. Immunity. 2019 Nov 19;51(5):840-855.e5 - PubMed
  21. Immunity. 2019 Dec 17;51(6):1043-1058.e4 - PubMed
  22. Cancer Res. 2017 Mar 1;77(5):1075-1082 - PubMed
  23. Clin Cancer Res. 2021 Mar 1;27(5):1371-1380 - PubMed
  24. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  25. Am J Pathol. 2018 Jun;188(6):1478-1485 - PubMed
  26. PLoS Genet. 2020 Feb 14;16(2):e1008641 - PubMed
  27. Cancer Cell. 2020 Oct 12;38(4):489-499.e3 - PubMed
  28. Immunity. 2019 Jan 15;50(1):195-211.e10 - PubMed
  29. Ann Oncol. 2018 Aug 1;29(8):1807-1813 - PubMed
  30. Clin Cancer Res. 2019 Apr 1;25(7):2174-2184 - PubMed
  31. Oncotarget. 2017 Dec 4;9(12):10284-10293 - PubMed
  32. Cancer Immunol Res. 2019 Sep;7(9):1384-1389 - PubMed
  33. Clin Cancer Res. 2018 Nov 1;24(21):5471-5481 - PubMed
  34. Clin Cancer Res. 2019 Aug 1;25(15):4820-4831 - PubMed
  35. Medicine (Baltimore). 2019 Sep;98(38):e17257 - PubMed
  36. Clin Cancer Res. 2016 Apr 15;22(8):1969-77 - PubMed
  37. Nature. 2019 Dec;576(7787):465-470 - PubMed
  38. Cancer Discov. 2020 Sep;10(9):1374-1387 - PubMed
  39. Sci Adv. 2015 Nov 06;1(10):e1500845 - PubMed
  40. Clin Cancer Res. 2020 Apr 15;26(8):2047-2064 - PubMed
  41. Nat Genet. 2018 May;50(5):645-651 - PubMed
  42. JAMA Oncol. 2019 Apr 1;5(4):471-478 - PubMed
  43. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32 - PubMed
  44. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44 - PubMed
  45. Sci Immunol. 2016 Dec 23;1(6): - PubMed
  46. Clin Cancer Res. 2018 Nov 15;24(22):5585-5593 - PubMed

Publication Types

Grant support